MedTrace Logo

Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.

NCT05435755 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-10-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of multiple treatments of hAESCs treatments, while exploring the effectiveness of hAESCs treatments for PD.

Conditions

Interventions

BIOLOGICAL

hAESCs treatment

Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.

BIOLOGICAL

placebo (saline)

2 times placebo (normal saline) injections as control group

Sponsors & Collaborators

  • Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

    collaborator INDUSTRY

  • Shanghai East Hospital

    lead OTHER

Principal Investigators

  • Jingwen Wu, Dr · Shanghai East Hospital, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-02
Primary Completion
2023-07-30
Completion
2023-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05435755 on ClinicalTrials.gov